Overview

A Study Utilizing Escitalopram in Glioma Patients

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This pilot study will include grade IV glioma patients treated with SSRIs during approximately a 17 week study period. Changes in cognition and evaluation of psychosocial factors from baseline to after 17 weeks of treatment with SSRI study drug will be calculated.
Phase:
Phase 2
Details
Lead Sponsor:
Nicole Shonka
Treatments:
Citalopram
Dexetimide